Amgen is cutting the list price of its new cholesterol-lowering drug by nearly 60 percent, a move the company says is intended to make the product more affordable for more patients.
At $5,850 per year, evolocumab (Repatha) won’t be cheap. But it will now be closer in price to another FDA-approved medicine in its class, which is sold by Regeneron Pharmaceuticals (NASDAQ: REGN).
The Amgen drug and Regeneron’s alirocumab (Praluent) both block PCSK9, an enzyme that hinders the body’s ability to clear LDL-C, the so-called “bad cholesterol,” from the bloodstream. When these drugs won FDA approval in 2015, their $14,000… Read more »
UNDERWRITERS AND PARTNERS